The preliminary results from three clinical trials administering gene therapy to address deafness from otoferlin mutations mark inspiring and incredible progress in hearing healthcare.
The Boston-based startup hopes to advance its products into clinical trials in the next 2-3 years, CEO says.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Clearwater Clinical views a self-directed hearing test it developed as a way to ensure more people have their hearing assessed from school aged children to aging baby boomers as well as for people who have cochlear implants.
What's called a Versatile Extra-Sensory Transducer could be a non-invasive, less expensive alternative to the cochlear implant for deaf people.